Tag: Cholinergic precursor / nucleotide

  • CDP-Choline (Citicoline)

    Cholinergic precursor / nucleotide

    Cytidine 5′-diphosphocholine, an endogenous nucleotide intermediate in phosphatidylcholine synthesis with neuroprotective and cognitive enhancement applications.

    Abstract

    Citicoline (cytidine 5′-diphosphocholine, CDP-Choline; CAS 987-78-0; molecular formula C14H26N4O11P2; molecular weight 488.32) is an endogenous nucleotide intermediate in the Kennedy pathway for phosphatidylcholine biosynthesis. Exogenous citicoline is hydrolyzed in the gut to cytidine and choline, which are absorbed independently and reassembled centrally as needed. The bioavailability profile differs from alpha-GPC: citicoline does not cross the blood-brain barrier intact at therapeutic concentrations; the elevation in central choline derives from increased availability of the precursor pools. The compound is approved as a medicine in many countries (Italy, Spain, Japan, Mexico, much of Latin America) for ischemic stroke, traumatic brain injury, and chronic cerebrovascular disease. Large randomized trials (ICTUS, COBRIT) have produced mixed results; meta-analysis suggests modest benefit in acute stroke recovery and chronic cognitive impairment with effect sizes in the 0.2 to 0.4 range. The compound is sold as a dietary supplement in the United States. Pharmacokinetics: plasma half-life of cytidine and choline components is several hours after dissociation; the CDP-Choline structure itself is not detectable in serum after oral administration. Excellent safety profile with rare serious adverse events.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.